Akebia Therapeutics, Inc.

Total Valuation

Akebia Therapeutics, Inc. carries a market capitalization of 193.25M, placing it among publicly traded companies globally. Its enterprise value stands at 209.21M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Akebia Therapeutics, Inc. currently has 271.74M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 1.39, and the price-to-book ratio stands at 12.38.

Enterprise Valuation

On an enterprise value basis, Akebia Therapeutics, Inc. trades at an EV/EBITDA multiple of 73.32 and an EV/FCF ratio of 3.41. The EV/Sales ratio of 0.96 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 96.21 provides insight into valuation relative to core operating earnings.

Financial Position

Akebia Therapeutics, Inc. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 219.72, indicating elevated leverage, while an interest coverage ratio of -0.67 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Akebia Therapeutics, Inc. has paid 1.82M in income taxes, reflecting an effective tax rate of 53.25.

Stock Price Statistics

Akebia Therapeutics, Inc.'s stock has declined approximately -77.93038% over the past 52 weeks. The 50-day moving average sits at 0.89, while the 200-day moving average is 1.18.

Income Statement

Over the trailing twelve months, Akebia Therapeutics, Inc. generated 219.06M in revenue and converted that into -29.67M in net income, yielding earnings per share of -0.11. EBITDA reached -11.63M, while operating income came in at -13.18M.

Balance Sheet

Akebia Therapeutics, Inc. holds 155.55M in cash and equivalents against 54.97M in total debt, resulting in a net debt position of -105.98M. Total book value stands at 25.02M, with working capital of 68.69M providing operational flexibility.

Cash Flow

Akebia Therapeutics, Inc. produced 41.55M in operating cash flow over the past twelve months. After subtracting -1.29M in capital expenditures, free cash flow totaled 40.26M - equivalent to 0.15 per share.

Margins

Akebia Therapeutics, Inc. operates with a gross margin of 79.63, reflecting its pricing power and cost economics. The operating margin of -6.02 and net profit margin of -13.54 provide insight into operational efficiency.

Dividends & Yields

Scores

Akebia Therapeutics, Inc. posts an Altman Z-Score of -6.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.